



Wyoming  
Department  
of Health

Division of Healthcare Financing

# Medicaid Pharmacy News

Dear Providers:

February 10, 2015

## **DIABETIC TEST STRIP LIMITS**

Effective February 18, 2015, Wyoming Medicaid clients that are insulin dependent will be limited to ten (10) test strips per day and clients that are non-insulin dependent will be limited to four (4) test strips per day. Any claims exceeding these limits will require a prior authorization.

## **REQUIRED MINIMUM DAY SUPPLIES**

Without prior authorization, Wyoming Medicaid will now require the following medications to be dispensed with the corresponding minimum day supplies:

- Proair, Ventolin, and Proventil Inhalers will be limited to at least a sixteen (16) day supply.
- Medroxyprogesterone Acetate IM suspension will be limited to at least an eighty-four (84) day supply.
- Lupron injections will be limited to at least a twenty-eight (28) day supply.
- Inhaled Tobramycin products will be limited to at least a fifty-six (56) day supply.

As a reminder, Wyoming Medicaid requires that the day supply for ALL prescriptions must equal the quantity of the medication dispensed divided by the daily dose prescribed. If, the day supply is calculated to be less than the minimum day supplies listed above, please call the GHS pharmacy help desk at 877-209-1264. An override may be given if the day supply is verified through the calculation explained above. Claims that do not meet the requirement stated above when calculating day supply could be subject to subsequent recovery and possible future audit proceedings.

## **NON-MATCH DATE OF BIRTH**

If a pharmacy receives a rejection for non-match date of birth, the pharmacy should call the GHS pharmacy help desk at 877-209-1264 to verify that the client ID being used is for the correct client.

## **PREFERRED DRUG LIST UPDATES**

- Generic analgesic hydrocodone products have been added to the PDL as preferred short-acting C-II's. Zohydro ER and Hysingla ER are non-preferred long-acting C-II's and will require State approval.
- Otezla will now be approved for the additional diagnosis of plaque psoriasis.
- Tanzeum and Trulicity are non-preferred GLP-1 receptor agonists and will require a ninety (90) day trial and failure of both metformin AND Victoza within the last year.
- Plegridy is a non-preferred MS Agent and will require the trial and failure of Avonex or Betaseron AND Copaxone prior to approval.
- Ospheha will not be covered by Wyoming Medicaid.
- Topiramate ER sprinkle capsules will be limited to those clients that have a diagnosis of epilepsy.
- To receive non-preferred antidepressants, the required trials of preferred antidepressants must be completed within the last two (2) years.